Literature DB >> 9101441

Altered properties of high density lipoprotein subfractions in obese subjects.

T Sasahara1, T Yamashita, D Sviridov, N Fidge, P Nestel.   

Abstract

Human HDL are heterogeneous in their metabolism and comprise small, nascent pre-beta-HDL and more mature alpha-HDL. Evidence exists that pre-beta 1-HDL is the initial acceptor of cellular free cholesterol, which then transfers sequentially to other pre-beta species and then, after esterification, into alpha-HDL. As HDL particles are themselves transformed during this process, we postulated that in disorders in which HDL-cholesterol is low, such as obesity, the distribution of HDL particles may be disturbed. In this study, we analyzed the HDL profile in 23 obese and 18 lean subjects, and further investigated the effects of dietary change in 15 obese subjects. HDL were separated by two-dimensional nondenaturing electrophoresis and the apoA-I content in each fraction was quantified. alpha 1-HDL in obese subjects was significantly lower (P < 0.001) and alpha 2-, alpha 3-, and pre-beta 1-HDL were significantly higher (P < 0.05 for alpha 2-HDL, P < 0.001 for alpha 3- and pre-beta 1-HDL) than in lean subjects. On stepwise regression analysis, body mass index accounted for 52% (negatively) of the variance in alpha 1-HDL and for 16% and 33% (positively) for the variances in alpha 3- and pre-beta 1-HDL, respectively. alpha 1- and pre-beta 3-HDL increased significantly after low-fat, oleic acid-rich, or alpha-linolenic acid-rich diets. The profile of alpha-HDL particles and also of pre-beta-HDL particles therefore shifted to smaller species in obese subjects, and this was influenced by dietary fat. Increased pre-beta 1-HDL-apoA-I in obese subjects is likely to derive from increased HDL catabolism but may also reflect diminished transformation of pre-beta 1- to pre-beta 2-HDL which might reduce capacity for reverse cholesterol transport and partly explain lower HDL-cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9101441

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.

Authors:  Orlando M Gutiérrez; Suzanne E Judd; Marguerite R Irvin; Degui Zhi; Nita Limdi; Nicholette D Palmer; Stephen S Rich; Michèle M Sale; Barry I Freedman
Journal:  Nephrol Dial Transplant       Date:  2015-07-06       Impact factor: 5.992

2.  BMI modifies the association between serum HDL cholesterol and stroke in a hypertensive population without atrial fibrillation.

Authors:  Y Yu; L Hu; X Huang; W Zhou; H Bao; X Cheng
Journal:  J Endocrinol Invest       Date:  2020-05-13       Impact factor: 4.256

3.  High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol.

Authors:  Amar A Sethi; Maureen Sampson; Russell Warnick; Nehemias Muniz; Boris Vaisman; Børge G Nordestgaard; Anne Tybjaerg-Hansen; Alan T Remaley
Journal:  Clin Chem       Date:  2010-05-28       Impact factor: 8.327

4.  Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease.

Authors:  Beatriz Talayero; Liyun Wang; Jeremy Furtado; Vincent J Carey; George A Bray; Frank M Sacks
Journal:  J Lipid Res       Date:  2014-06-25       Impact factor: 5.922

Review 5.  New insights into the mechanism of low high-density lipoprotein cholesterol in obesity.

Authors:  Hao Wang; Dao-Quan Peng
Journal:  Lipids Health Dis       Date:  2011-10-12       Impact factor: 3.876

Review 6.  Interaction between adipocytes and high-density lipoprotein:new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis.

Authors:  Tianhua Zhang; Jin Chen; Xiaoyu Tang; Qin Luo; Danyan Xu; Bilian Yu
Journal:  Lipids Health Dis       Date:  2019-12-16       Impact factor: 3.876

Review 7.  HDL Composition, Heart Failure, and Its Comorbidities.

Authors:  Ahmed Diab; Carla Valenzuela Ripoll; Zhen Guo; Ali Javaheri
Journal:  Front Cardiovasc Med       Date:  2022-03-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.